Objective: Relapse of AML after allogeneic hematopoietic stem cell transplantation (HSCT) has a poor prognosis, and standard of care therapy is lacking. Early (<6 months) relapse is associated with dismal outcome, while the majority of relapses occur early after transplantation. A more precise indication which patients could benefit from reinduction therapy is warranted.
GvL responses after postallogeneic HSCT AML relapse. 3, 14 However, in case of cord blood transplantation DLI is unavailable, and not all patients are eligible for DLI as it may re-induce or exacerbate graftversus-host disease (GvHD). In case of an early detected molecular or cytogenetic relapse, DLI can be performed without reinduction therapy. Alternatively, a second allogeneic HSCT with a new donor can be performed. DLI or a second allogeneic HSCT is most successful in female patients with a late relapse (>6 months) of cytogenetically favorable AML and when DLI is given once complete remission is achieved. [1] [2] [3] 14 In this study, we retrospectively analyzed outcomes of patients with postallogeneic HSCT AML relapse, in whom the decision to offer curative or best supportive care therapy was based on factors described above, a per-patient analysis of physical fitness and comorbidity, and individual considerations of the patient.
| PATIENTS AND ME THODS

| Patients
The medical records of all 83 adult patients (>17 years of age) with myeloid malignancies who had received an allogeneic HSCT at the Amsterdam University Medical Centers between January 1, 2010, and December 31, 2016, and in whom disease relapse occurred before December 31, 2017, were reviewed. Eighty of these patients were diagnosed with AML, and three patients underwent allogeneic HSCT for chronic myelomonocytic leukemia (CMMoL) or high-risk myelodysplastic syndrome (MDS with excess of blasts (EB) II). Patients were classified according to the WHO Classification of myeloid neoplasms and acute leukemia 2008 (hereafter WHO 2008 Classification). 15 Risk was defined according to the risk group classification used in the then active HOVON 92, HOVON 102, and HOVON 132 trials (Table S1) in which most patients participated. The few patients not participating in these trials were classified and treated according these trials. This prognostic classification is based on known risk factors with respect to cytogenetic abnormalities and molecular alterations, white blood cell count (WBC), and attainment of early complete remission. The cytogenetic abnormalities and molecular alterations that were used for the risk assessment of these patients are in line with the prognostic risk groups of the European Leukemia Net 2010. 16 Six patients received one or more prophylactic donor lymphocyte infusions (DLI) after allogeneic HSCT, before relapse. Immunologic consolidation with consecutive DLI was started at least 6 weeks after recovery form chemotherapy-induced neutropenia. In accordance with the Declaration of Helsinki, written informed consent was obtained from all patients.
| Statistical analysis
The collected data were coded and anonymously processed. The analyses were done using IBM SPSS Statistics 24.0.0.1 software. 
| RE SULTS
| Patient characteristics
Demographics of the 83 patients who had received an allogeneic HSCT for AML or high-risk MDS between January 1, 2010 and December 31, 2016, and relapsed before December 31, 2017, are shown in Table 1 . Three patients (4%) who had been initially classified as good risk had received an allogeneic HSCT because of relapsed AML. Four of the patients had an intracranial or leptomeningeal localization of their relapse, and no AML blasts in the bone marrow. Median time of follow-up for survivors was 220 weeks, ranging from 49 to 391 weeks.
| Curative treatment vs best supportive care
Patients were classified into two groups: patients who were treated with curative intent (CIT group) and patients who refrained from curative treatment and received best supportive care either at their own request or as advised by the treating physician (BSC group).
Treatment with curative intent was considered in all patients that were fit enough according to the treating physician, in particular when relapse occurred more than 6 months after allogeneic HSCT.
Despite the fact that relapse less than 6 months after allogeneic HSCT is considered a very poor prognostic factor, 11 patients with such an early relapse received reinduction chemotherapy, in most cases because of young age, excellent clinical condition, and very high motivation of the patient. The decision to treat or to refrain from curative treatment was always made after extensive elaboration between physicians and in close consultation with the patient and his/her family.
Fifty (60%) of the patients were treated with curative intent of which 13 (26%) were still alive at the end of follow-up (16% of all patients in this study; Table 2 ). Patients in the CIT group were younger than BSC patients (median 53 vs 58 years, P = .043), had significantly lower bone marrow blast counts (median 21% vs 38%, P = .025), and had lower cytogenetical/molecular risk characteristics (r = .226; P = .040; Table 2 ). When excluding the relapses that were restricted to the central nervous system, no significant difference in bone marrow blast count was observed between the BSC and CIT groups (median 38% vs 24%, P = .082). No differences could be assessed for the WHO 2008 Classification as the subgroups were too small to properly evaluate. The time between allogeneic HSCT and relapse ranged from 3 to 63 weeks for the BSC group and 5-187 weeks for the CIT group. Overall, prognosis was very poor, with a 2-year survival of 17% for the whole group ( Figure 1 ). Median time of survival was 16 weeks for the CIT group and only 3 weeks for the best supportive care group (Table 2 ).
In the CIT group, two patients (4%) with low blast counts (8% and 10%, respectively) received DLI without reinduction therapy, in 23 patients (46%) immunosuppressants were tapered and stopped, 10 patients (20%) were treated with a hypomethylating agent, of whom 3 (6%) received this agent as single treatment, and 22 patients (44%)
were treated with high-dose chemotherapy. High-dose chemotherapy consisted of high-dose cytarabine in the majority of cases, and FLAG (fludarabine, cytarabine, G-CSF) or other regimens in the other patients (Table S2 ). Four patients had an isolated central nervous system relapse with intracranial chloroma or leptomeningeal AML localization. These patients were in the CIT group and received intrathecal cytarabine, in some combined with systemic cytarabine, intrathecal methotrexate, or radiotherapy. Two of these patients attained complete remission and were alive at 6.5 and 7.5 years after their relapse. DLI is given as consolidation therapy to those patients that obtained complete remission. Most patients that did not receive consolidation with DLI had rapid progression of the disease and/or failing of reinduction therapy. For 2 patients, the donor was not (cord blood HSCT) or no longer available; the rest of the patients did not receive DLI because of GvHD.
| Determinants of survival
The CIT group was then split into survivors and non-survivors, as per end of follow-up (December 31, 2017), in order to identify prognostic relevant differences between these two groups (Figure 2 ). In one patient, AML relapsed after she had obtained complete remission following reinduction therapy with curative intent (tapering of immunosuppressants followed by hypomethylating therapy). This patient was still alive but with active AML at the end of follow-up and therefore evaluated in the survivor group (Table S2 , patient ID_030).
There was no difference in age, type of transplantation, conditioning regimen, bone marrow blast percentage at time of relapse or the time between transplantation, and relapse between survivors and non-survivors. However, survivors had more often received highdose reinduction chemotherapy (69% vs 35%, P = .035) and immunologic consolidation therapy (69% vs 22%, P = .003; Table 3 ). In addition, survivors had more often reached complete remission after allogeneic HSCT vs after 6 months was taken as a cutoff, no significant difference in survival was observed. In fact, 7 of the 12 disease-free survivors had received reinduction therapy despite early (<6 months after allogeneic HSCT) relapse (Table S2 ). The size of the patient group did not allow for outcome analyses of molecular and cytogenetic risk groups. in patients with relapsed AML after allogeneic HSCT is in line with other studies (Figure 1 ). 17, 18 Outcome was best for those patients who were fit enough to receive high-dose reinduction therapy followed by immunologic consolidation therapy with DLI or 2nd allogeneic HSCT in complete remission. We confirmed previous reports showing that time between allogeneic HSCT and relapse was significantly correlated with survival, with very early relapses (<3 months) having a dismal prognosis. 3, 4, 19, 20 Most importantly, we found that early relapse, between 3 and 6 months after allogeneic HSCT, did not have a worse prognosis compared with relapse >6 months after allogeneic HSCT. This finding is of clinical significance, as the majority of relapses occurs within 6 months after allogeneic HSCT. Given that 2nd relapses may occur late, but always sooner than the first relapse, it is important to have a sufficient period of follow-up in order to identify the long-term survivors. With a median time of follow-up of over 4 years, which was longer than the initial time period between allogeneic HSCT and relapse in all but one patient, we are confident that the patients that we qualified as non-relapse survivors are likely to be cured.
| D ISCUSS I ON
Previous analyses on survival after relapse focused on patients treated with curative intent only, inherently containing the risk of selection bias. In our study, we included all patients with relapsed AML or high-risk MDS after allogeneic HSCT in our center.
Comparison of the CIT and BSC groups, defined based on intention to treat, revealed that patients who according to their physicians did not qualify for curative-intent therapy or choose to refrain from intensive therapy (the latter being a minority of cases) were a little older (53 [range 18-71] vs 58 years, P = .04) and had higher rates of very poor-risk AML at primary diagnosis ( We confirm previous reports demonstrating that re-obtaining complete remission is an important prognostic determinant. 3, 4, [20] [21] [22] 24 Only 2 of the 28 patients that did not reach complete remission after curative-intent therapy survived ( Figure 2 and Figure 2 ). AML relapse after allogeneic HSCT is associated with a dysregulation in immune function pathways such as HLA expression by AML blasts that may help AML cells evade donor immune responses. 27 Immunologic consolidation can be effective when newly infused donor immune cells that are naive with regard to the patient's AML elicit a GvL response independent of HLA-related antigen presentation, for example, to targets that are expressed on the membrane of AML blasts. 28, 29 Thus, as also suggested by other studies, immunological consolidation is of importance for survival in this setting. GvHD occurred in some but not all surviving patients suggesting that immunologic consolidation can also be effective when it does not lead to GvHD. 3 With new therapies for AML emerging, the arsenal to treat AML relapse after allogeneic HSCT is expanding. The Bcl2 inhibitor Venetoclax in combination with hypomethylating agents has shown promising results in patients with relapsed or refractory AML. 30 A wide range of mutation-targeting agents is available, most of them tyrosine-kinase inhibitors directed against FLT3. 31 Adoptive transfer of natural killer (NK) cells and T cells targeting AML-specific antigens are under investigation, and chimeric antigen receptor (CAR) T cells and bispecific T-cell engagers targeting CD33 and CD123 are being developed. 13, 32 Prospective clinical trials are required to investigate the potential of these novel therapies in the treatment of AML relapse after allogeneic HSCT.
Taken together, while relapsed AML and MDS after allogeneic HSCT have a dismal prognosis, a subset of patients may benefit from curative-intent therapy. Selection of candidates remains a challenge and should be based on patient's fitness as determined by the team of treating physicians and on the motivation of the patient. In patients deemed fit, reinduction therapy may offer a prospect for cure.
Our data suggest that more patients might be eligible for intensive reinduction treatment than previously assumed as time between transplantation and relapse should only be taken into account in case of very early relapses, for example, <3 months after allogeneic HSCT, in which case outcome is dismal. Reinduction therapy that fails may prolong life expectancy but most often at the expense of quality of life. If complete remission is obtained, however, chances for cure improve significantly, in particular when immunologic consolidation therapy to reinvigorate or redirect GvL responses is given.
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